The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 21, 2023

Filed:

Dec. 30, 2020
Applicant:

Pharmajor International, Luxembourg, LU;

Inventors:

Guillaume El Glaoui, Luxembourg, LU;

Mehdi El Glaoui, Luxembourg, LU;

Philippe Perrin, Paris, FR;

Stéphane Droupy, Nimes, FR;

Véronique Agathon-Meriau, Luxembourg, LU;

Assignee:

PHARMAJOR INTERNATIONAL, Luxembourg, LU;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4045 (2006.01); A61P 15/16 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4045 (2013.01); A61K 9/0053 (2013.01); A61K 9/16 (2013.01); A61K 9/5078 (2013.01); A61P 15/16 (2018.01); A61K 45/06 (2013.01);
Abstract

The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.


Find Patent Forward Citations

Loading…